The U.S. Food and Drug Administration (FDA) has approved revised labeling for Micotil 300 (tilmicosin injection) that addresses risks to people handling or administering the drug. Human injection with Micotil 300 can lead to severe cardiac effects and death.
Elanco Animal Health, the sponsor of Micotil 300, worked with the FDA to decrease the risk of accidental human injection and other potential routes of exposure. The drug is now packaged inside a tamper-proof shroud and access to the product requires a quick-connect device, which is provided with a tube-fed safety syringe by Elanco or…
